Treating Infectious Diseases In A Microbial World

Humans coexist with millions of harmless microorganisms, but emerging diseases, resistance to antibiotics, and the threat of bioterrorism are forcing scientists to look for new ways to confront the microbes that do pose a danger. This report identifies innovative approaches to the development of antimicrobial drugs and vaccines based on a greater understanding of how the human immune system interacts with both good and bad microbes. The report concludes that the development of a single superdrug to fight all infectious agents is unrealistic.

A History of Infectious Diseases and the Microbial World offers readers answers to specific questions, as well as the challenge of a narrative that will stimulate their curiosity and encourage them to ask questions about the theory, practice, and assumptions of modern medicine. This work provides a broad introductory overview of the history of major infectious diseases, including their impact on different populations, the recognition of specific causative agents, and the development of methods used to prevent, control, and treat them. By stressing the major themes in the history of disease, this book allows readers to relate modern concerns to historical materials. It places modern developments concerning infectious diseases within their historical context, illuminating the relationships between patterns of disease and social, cultural, political, and economic factors. Upon completing this volume, readers will be prepared to answer contemporary questions concerning the threat of newly-emerging infectious diseases, potentially devastating pandemics, and the threat of bioterrorism. One will gain a precise understanding of the nature of different kinds of pathogens, the unique mechanisms behind disease transmission, and the means used to control, prevent, and treat infectious disease. Although only a few of these deadly illnesses can be addressed in detail, those that are discussed include: malaria, leprosy, bubonic plague, tuberculosis, syphilis, diphtheria, cholera, yellow fever, poliomyelitis, HIV/AIDS, and influenza.

The resistance topic is timely given current events. The emergence of mysterious new diseases, such as SARS, and the looming threat of bioterrorist attacks remind us of how vulnerable we can be to infectious agents. With advances in medical technologies, we have tamed many former microbial foes, yet with few new antimicrobial agents and vaccines in the pipeline, and rapidly increasing drug resistance among infectious microbes, we teeter on the brink of loosing the upperhand in our ongoing struggle against these foes, old and new. The Resistance Phenomenon in Microbes and Infectious Disease Vectors examines our understanding of the relationships among microbes, disease vectors, and human hosts, and explores possible new strategies for meeting the challenge of resistance.

Microbes – can’t live with them, can’t live without them. Increasingly, we’re finding out that our microbiota (the microbes that live on us) are essential for our wellbeing – they provide us with nutrients and vitamins and play a key role in developing our immune system. On the other hand, they are responsible for a great deal of misery, as they are major causes of death and debility around the world. As well as our own microbiota turning against us, there are lots of other microbes out in the wider world that can seriously damage, or even kill, those they infect. The current pandemic of COVID-19 shows the devastating effect that an infectious disease can have – our lives have been turned upside down. If you live in a developed country, you’re not likely to get killer diseases such as ebola and cholera, but you do have a high chance of catching other infections that can have a significant impact on your wellbeing. This book focuses on those infections you’re most likely to go down with, and supplies the answers to the following questions about them: Which infectious diseases are we likely to come across? How common are they? What microbes cause them? What happens to our bodies during an infection? How are the resulting illnesses treated? How can we avoid getting them? This book covers nearly 60 infectious diseases that people living in developed countries are likely to experience at some point during their life. It also has an introductory chapter that describes, in everyday language, the basic principles of microbiology and infectious diseases. Each chapter is lavishly illustrated, has interesting, relevant inserts, and provides a list of web-accessible suggestions for further reading.

Infectious diseases are a global hazard that puts every nation and every person at risk. The recent SARS outbreak is a prime example. Knowing neither geographic nor political borders, often arriving silently and lethally, microbial pathogens constitute a grave threat to the health of humans. Indeed, a majority of countries recently identified the spread of infectious disease as the greatest global problem they confront. Throughout history, humans have struggled to control both the causes and consequences of infectious diseases and we will continue to do so into the foreseeable future. Following up on a high-profile 1992 report from the Institute of Medicine, Microbial Threats to Health examines the current state of knowledge and policy pertaining to emerging and re-emerging infectious diseases from around the globe. It examines the spectrum of microbial threats, factors in disease emergence, and the ultimate capacity of the United States to meet the challenges posed by microbial threats to human health. From the impact of war or technology on disease emergence to the development of enhanced disease surveillance and vaccine strategies, Microbial Threats to Health contains valuable information for researchers, students, health care providers, policymakers, public health officials. and the interested public.

Examining the enormous potential of microbiome manipulation to improve health Associations between the composition of the intestinal microbiome and many human diseases, including inflammatory bowel disease, cardiovascular disease, metabolic disorders, and cancer, have been elegantly described in the past decade. Now, whole-genome sequencing, bioinformatics, and precision gene-editing techniques are being combined with centuries-old therapies, such as fecal microbiota transplantation, to translate current research into new diagnostics and therapeutics to treat complex diseases. Bugs as Drugs provides a much-needed overview of microbes in therapies and will serve as an excellent resource for scientists and clinicians as they carry out research and clinical studies on investigating the roles the microbiota plays in health and disease. In Bugs as Drugs, editors Robert A. Britton and Patrice D. Cani have assembled a fascinating collection of reviews that chart the history, current efforts, and future prospects of using microorganisms to fight disease and improve health. Sections cover traditional uses of probiotics, next-generation microbial therapeutics, controlling infectious diseases, and indirect strategies for manipulating the host microbiome. Topics presented include: How well-established probiotics support and improve host health by improving the composition of the intestinal microbiota of the host and by modulating the host immune response. The use of gene editing and recombinant DNA techniques to create tailored probiotics and to characterize next-generation beneficial microbes. For example, engineering that improves the anti-inflammatory profile of probiotics can reduce the number of colonic polyps formed, and lactobacilli can be transformed into targeted delivery systems carrying therapeutic proteins or bioengineered bacteriophage. The association of specific microbiota composition with colorectal cancer, liver diseases, osteoporosis, and inflammatory bowel disease. The gut microbiota has been proposed to serve as an organ involved in regulation of inflammation, immune function, and energy homeostasis. Fecal microbiota transplantation as a promising treatment for numerous diseases beyond C. difficile infection. Practical considerations for using fecal microbiota transplantation are provided, while it is acknowledged that more high-quality evidence is needed to ascertain the importance of strain specificity in positive treatment outcomes. Because systems biology approaches and synthetic engineering of microbes are now high-throughput and cost-effective, a much wider range of therapeutic possibilities can be explored and vetted.